Anti-glomerular basement membrane vasculitis

Autoimmun Rev. 2023 Jan;22(1):103212. doi: 10.1016/j.autrev.2022.103212. Epub 2022 Oct 14.

Abstract

Antiglomerular basement membrane disease (anti-GBM) is a rare life-threatening autoimmune vasculitis that involves small vessels and it is characterized by circulating autoantibodies directed against type IV collagen antigens expressed in glomerular and alveolar basement membrane. The typical clinical manifestations are the rapidly progressive glomerulonephritis and the alveolar hemorrhage. The diagnosis is usually confirmed by the detection of anti-GBM circulating antibodies. If not rapidly recognized, anti-GBM disease can lead to end stage kidney disease (ESKD). An early diagnosis and prompt treatment with immunosuppressive therapies and plasmapheresis are crucial to prevent a poor outcome. In this review, we discuss the primary form of anti-GBM (the so called Goodpasture syndrome) but also cases associated with other autoimmune diseases such as antineutrophil-cytoplasmic-antibody (ANCA) vasculitis, membranous nephropathy, IgA nephritis and systemic lupus erythematosus (SLE), as well as the few cases of anti-GBM vasculitis complicating kidney transplantation in the Alport syndrome.

Keywords: Alveolar hemorrhage; Anti-neutrophil cytoplasm antibody; Goodpasture syndrome; Plasmapheresis; Pulmonary-renal syndrome; Rapidly progressive glomerulonephritis.

Publication types

  • Review

MeSH terms

  • Anti-Glomerular Basement Membrane Disease* / diagnosis
  • Anti-Glomerular Basement Membrane Disease* / therapy
  • Antibodies, Antineutrophil Cytoplasmic
  • Autoantibodies
  • Basement Membrane
  • Glomerulonephritis*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Vasculitis* / complications
  • Vasculitis* / diagnosis
  • Vasculitis* / therapy

Substances

  • Immunosuppressive Agents
  • Autoantibodies
  • Antibodies, Antineutrophil Cytoplasmic